Andreas Halvorsen’s Ginkgo Bioworks DNA Stock Holding History

Andreas Halvorsen’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.4M	Hold	3,577,128	–	–	0.1%	76
2026 Q1	$21.9M	Hold	3,577,128	–	–	0.06%	73
2025 Q4	$29.7M	Hold	3,577,128	–	–	0.08%	74
2025 Q3	$52.2M	Hold	3,577,128	–	–	0.14%	70
2025 Q2	$40.2M	Hold	3,577,128	–	–	0.12%	77
2025 Q1	$20.4M	Hold	3,577,128	–	–	0.06%	83
2024 Q4	$35.1M	Hold	3,577,128	–	–	0.11%	78
2024 Q3	$29.2M	Hold	3,577,128	–	–	0.11%	78
2024 Q2	$47.8M	Hold	3,577,128	–	–	0.18%	70
2024 Q1	$166M	Hold	3,577,128	–	–	0.62%	40
2023 Q4	$242M	Hold	3,577,128	–	–	0.89%	38
2023 Q3	$259M	Hold	3,577,128	–	–	1.05%	30
2023 Q2	$266M	Hold	3,577,128	–	–	1.09%	35
2023 Q1	$190M	Buy	3,577,128 +2,000,000	+127%	+$127M	0.89%	33
2022 Q4	$107M	Sell	1,577,128 -968,725	-38%	-$89.1M	0.53%	49
2022 Q3	$318M	Buy	2,545,853 +1,868,750	+276%	+$223M	1.47%	25
2022 Q2	$64.5M	Sell	677,103 -599,276	-47%	-$73.1M	0.29%	61
2022 Q1	$206M	Sell	1,276,379 -7,200,000	-85%	-$1.4B	0.83%	35
2021 Q4	$2.82B	Hold	8,476,379	–	–	8.12%	1
2021 Q3	$3.93B	Buy	+8,476,379	New	+$4.13B	10.78%	1

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Andreas Halvorsen's DNA Position: Q2 2026 in Review

Andreas Halvorsen held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 3,577,128 shares worth $35.4M. The position accounts for 0.1% of the portfolio, ranked #76.

Andreas Halvorsen first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $3.93B in Q3 2021. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Andreas Halvorsen held 3,577,128 shares of Ginkgo Bioworks worth $35.4M as of Q2 2026.
Andreas Halvorsen left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up 0.1% of Andreas Halvorsen's portfolio in Q2 2026, its #76 holding.
Andreas Halvorsen first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
Andreas Halvorsen's Ginkgo Bioworks position peaked at $3.93B in Q3 2021.
183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Viking Global Investors's 13F filing for Q2 2026, filed 14 Aug 2026.